Guided Therapeutics (GTHP) Debt to Equity (2016 - 2025)
Historic Debt to Equity for Guided Therapeutics (GTHP) over the last 14 years, with Q3 2025 value amounting to -$0.02.
- Guided Therapeutics' Debt to Equity rose 9212.31% to -$0.02 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.02, marking a year-over-year increase of 9212.31%. This contributed to the annual value of -$0.03 for FY2024, which is N/A changed from last year.
- Guided Therapeutics' Debt to Equity amounted to -$0.02 in Q3 2025, which was up 9212.31% from -$0.02 recorded in Q2 2025.
- In the past 5 years, Guided Therapeutics' Debt to Equity ranged from a high of -$0.02 in Q2 2025 and a low of -$21.28 during Q1 2025
- For the 4-year period, Guided Therapeutics' Debt to Equity averaged around -$1.63, with its median value being -$0.12 (2021).
- Its Debt to Equity has fluctuated over the past 5 years, first crashed by 36851.69% in 2021, then skyrocketed by 9322.02% in 2025.
- Quarter analysis of 4 years shows Guided Therapeutics' Debt to Equity stood at -$0.12 in 2021, then surged by 72.23% to -$0.03 in 2022, then increased by 2.7% to -$0.03 in 2024, then soared by 43.86% to -$0.02 in 2025.
- Its last three reported values are -$0.02 in Q3 2025, -$0.02 for Q2 2025, and -$21.28 during Q1 2025.